Real-world experience with obinutuzumab in difficult-to-treat myositis: concise report of a case series

奥比努图库单抗 医学 美罗华 内科学 皮疹 间质性肺病 皮肌炎 肌炎 类风湿性关节炎 肿瘤科 CD20 疾病 物理疗法 外科 苯达莫司汀 奥图穆马 皮肤病科 重症监护医学 流行病学 痹症科 中性粒细胞减少症 托珠单抗
作者
Ivana Ilić,Sonali Narain,Galina S. Marder
出处
期刊:Rheumatology [Oxford University Press]
卷期号:65 (9)
标识
DOI:10.1093/rheumatology/keag435
摘要

OBJECTIVES: Idiopathic inflammatory myopathy (IIM) is an orphan systemic disorder with muscular, cutaneous and pulmonary involvement. B cell-directed therapies, including rituximab, belimumab and chimeric antigen receptor T-cell (CAR-T), have shown promise in altering disease outcome. We report the benefit of obinutuzumab in difficult -to- treat myositis patients. METHODS: The Northwell Rheumatology database was searched for obinutuzumab-treated patients (2019-24); five of them met 2017 EULAR/ACR classification criteria for IIM and were included in the analysis. Demographic, clinical, serological and imaging data were collected. Overall response was rated as complete, partial or no response based on clinical response and physician global assessment. Total improvement score was not calculated because data were collected retrospectively. Descriptive statistics were used for analyses. RESULTS: Of five patients, two had antisynthetase syndrome, one dermatomyositis (DM) and two overlap myositis. Most patients failed at least three immunosuppressive agents. The reason for obinutuzumab use was rituximab allergy and worsening of interstitial lung disease (ILD) and myositis activity (3/5), arthritis (2/5) and severe rash (1/5 patients), despite rituximab. After obinutuzumab 80% of patients had overall improvement by 3-6 months. Respiratory status improved/stabilized in all ILD patients. Two patients required second obinutuzumab cycle: one for recurrence and another for persistent disease with B cell re-population. One was lost to follow-up after the second cycle and was deemed a non-responder. At last observation, 4/5 patients had achieved a complete response. No hypogammaglobulinaemia, significant infections or hospitalizations were observed. CONCLUSION: Obinutuzumab was safe and provided durable improvement in difficult-to-treat myositis patients with rituximab allergy, further highlighting targeting the B-cell pathway.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星辰发布了新的文献求助10
刚刚
wHu完成签到 ,获得积分10
1秒前
小二郎的应助被霖槿采纳,获得10
1秒前
2秒前
fUCKaLL发布了新的文献求助10
2秒前
JeromineJade完成签到,获得积分10
2秒前
leo发布了新的文献求助10
3秒前
饺子发布了新的文献求助10
3秒前
4秒前
4秒前
河边的栏杆完成签到 ,获得积分10
4秒前
5秒前
5秒前
5秒前
汤汤杨杨完成签到,获得积分10
5秒前
天宇发布了新的文献求助10
5秒前
5秒前
5秒前
5秒前
何小何完成签到 ,获得积分10
5秒前
6秒前
balko发布了新的文献求助10
6秒前
李健的粉丝团团长的应助被hzr采纳,获得10
7秒前
幽默涵易完成签到 ,获得积分10
7秒前
克莱茵蓝色完成签到 ,获得积分10
7秒前
橙汁儿完成签到,获得积分10
7秒前
moriaty发布了新的文献求助20
7秒前
8秒前
JamesPei的应助被开心德地采纳,获得10
9秒前
9秒前
小明完成签到 ,获得积分10
9秒前
qiaobbbbb发布了新的文献求助10
10秒前
朱佳宁发布了新的文献求助10
10秒前
10秒前
灵巧的嚣发布了新的文献求助10
10秒前
称心傲柔完成签到 ,获得积分20
11秒前
痴情的银耳汤完成签到,获得积分10
11秒前
一二三完成签到,获得积分10
11秒前
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187652
求助须知:如何正确求助?哪些是违规求助? 9575758
关于积分的说明 21842805
捐赠科研通 7785538
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559480
邀请新用户注册赠送积分活动 2481963